An­ti­body mak­er Vac­cinex files $46M IPO tout­ing I/O com­bo drug; Replimune shoots for $100M-plus in IPO

→ Af­ter spend­ing over a decade build­ing out a pipeline of an­ti­body drugs to treat can­cer, neu­ro­log­i­cal and au­toim­mune dis­eases, Vac­cinex is rid­ing on this year’s IPO wave and seek­ing a $46 mil­lion raise.

With the in­fu­sion, the Rochester, NY-based biotech is look­ing to fund VX15, its SE­MA4D an­ti­body be­ing test­ed for Hunt­ing­ton’s dis­ease (a Phase II pro­gram grant­ed fast track and or­phan des­ig­na­tion), non-small cell lung can­cer as well as melanoma and os­teosar­co­ma. There’s al­so debt to re­pay and pre­clin­i­cal re­search to con­tin­ue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER